Orlando Agrippa

Orlando A. Agrippa is a British healthcare executive and technology entrepreneur specialising in data, analytics, artificial intelligence, and life sciences. He is the founder and chief executive officer of Sanius Health, a digital health and life sciences company. He advises NHS England on transformation and national data programmes and is a partner within one of the largest primary care groups, Modality Group.

Career From November 2010 to October 2013, Agrippa worked as the associate director of Business Informatics at Colchester Hospital University NHS Foundation Trust. From November 2013 to December 2015, he held the position of Deputy CIO and Transformation Director at Barts Health NHS Trust in London. He worked in data and analytics transformation at Guy's and St Thomas' NHS Foundation Trust and in parallel at Imperial College Healthcare NHS Trust and NHS Tayside in Scotland.

In January 2015, Agrippa moved to Australia to serve as the Director of Healthcare Analytics and Service Improvement for The Royal Melbourne Hospital and NorthWestern Mental Health until December 2016. Since September 2017, he has acted as a mentor for the NHS Clinical Entrepreneur Programme.

From April 2014 to September 2016, Agrippa served as the Group CEO of Draper& Dash, Healthcost, a provider of patient costing and benchmarking services that was later acquired by IQVIA. In February 2017, he founded RwHealth (originally Real World Health), an artificial intelligence and predictive analytics company based in London, where he remained as CEO until October 2022.

MobiHealthNews reported the RwHealth Series A round as approximately €7.2 million (around £6.1 million / US$8.4 million), led by Maven Capital Partners with participation from Guinness Asset Management and the Northern Powerhouse Investment Fund.

In early 2020, during the COVID-19 pandemic, Agrippa helped develop a predictive model to help NHS hospitals manage bed capacity and intensive care needs. He spent a year working with SEHA in Abu Dhabi on its COVID response across the region.

In 2021, Agrippa founded Sanius Health, a digital platform for patients with blood cancers, rare diseases, and chronic conditions, such as sickle cell disease. The platform was officially launched in early 2022. He invested over £2 million of his own money to start the company. The platform allows patients to track their own health data, which is then used by researchers and clinicians to improve treatment.

In 2023, Agrippa was named one of the "Top 100 Influential People" in the United Kingdom.

In January 2024, Sanius Health and Modality Partnership announced a ten-year collaboration valued at approximately £225 million, extending the Sanius Health AI platform to more than 500,000 patients across the UK. In October 2024, Health Tech News approved a wearable-technology study, conducted in partnership with Portsmouth Hospitals NHS Trust, with further collaboration with haematologist Dr Sanne Lugthart at University Hospitals Bristol and Weston NHS Foundation Trust.

In March 2026, Sanius Health acquired Kielo Research, a Zug-based Swiss patient-preference and patient-reported outcomes research firm founded in 2022. Also in March 2026, Sanius Health acquired TherapyAudit, a Cambridge-based digital cancer-therapy monitoring company, for an undisclosed cash consideration.

Agrippa has spoken publicly about his own diagnosis with a rare disease. He has stated that this personal experience led him to focus on technology that helps patients manage their own health data.

He hosts a podcast called The Future of Healthcare, which started in 2019.